Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1989 Feb;59(2):268–275. doi: 10.1038/bjc.1989.56

Breast cancer, prostaglandins and patient survival.

A Bennett 1, I F Stamford 1, D A Berstock 1, F Dische 1, L Singh 1, R P A'Hern 1
PMCID: PMC2247010  PMID: 2930691

Abstract

Prostaglandins may have both undesirable and desirable effects in malignant disease. Their possible roles in breast cancer were studied by examining the relationships between different variables and the amounts of prostaglandin-like material (PG-LM) extracted from 141 breast carcinomas. Univariate analysis indicates a direct correlation with patient age and menopausal status, with a greater yield from cancers of post- compared with pre-menopausal women. Tumours up to 2 cm diameter yielded more PG-LM than those measuring greater than 2-5 cm. Although there was also a direct correlation with bone metastasis near to the time of surgery, this was because no positive bone scans occurred in patients whose tumours yielded little total PG-LM (less than 16 ng PGE2 equivalents per g tissue). Since tumour PG-LM did not predict later spread to bone, and yields of greater than 16 ng g-1 were similar in the positive and negative bone scan groups, tumour PG-LM appears to be unimportant for skeletal metastasis. There was no obvious relationship of tumour PG-LM to the grade of malignancy, tumour type, amounts of fibrous tissue (and therefore malignant cells), invasion of blood vessels and lymphatics or presence of plasma cells. Multivariate analysis indicates that disease-free survival is longest with an intermediate production of tumour total PG-LM. Of the 82 patients now dead, the cause was attributed to metastatic disease in 69 cases. No relationship of PG-LM to the length of survival was seen with univariate or multivariate analysis. However, when just the post-menopausal patients who died within the first 3 postoperative years were analysed, there was a highly significant inverse correlation between the tumour total PG-LM and the time to death. The reason(s) for these different findings on overall survival compared with just the patients who died are not understood, but the results may indicate that one or more other variables must co-exist with a high tumour PG-LM to hasten death.

Full text

PDF
269

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BLOOM H. J., RICHARDSON W. W. Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer. 1957 Sep;11(3):359–377. doi: 10.1038/bjc.1957.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bennett A., Charlier E. M., McDonald A. M., Simpson J. S., Stamford I. F., Zebro T. Prostaglandins and breast cancer. Lancet. 1977 Sep 24;2(8039):624–626. doi: 10.1016/s0140-6736(77)92496-5. [DOI] [PubMed] [Google Scholar]
  3. Bennett A., Jarosik C., Sanger G. J., Wilson D. E. Antagonism of prostanoid-induced contractions of rat gastric fundus muscle by SC-19220, sodium meclofenamate, indomethacin or trimethoquinol. Br J Pharmacol. 1980;71(1):169–175. doi: 10.1111/j.1476-5381.1980.tb10922.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bennett A., McDonald A. M., Simpson J. S., Stamford I. F. Breast cancer, prostaglandins, and bone metastases. Lancet. 1975 May 31;1(7918):1218–1220. doi: 10.1016/s0140-6736(75)92197-2. [DOI] [PubMed] [Google Scholar]
  5. Bennett A., Stamford I. F., Unger W. G. Prostaglandin E2 and gastric acid secretion in man. J Physiol. 1973 Mar;229(2):349–360. doi: 10.1113/jphysiol.1973.sp010142. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Borah V., Shah P. N., Ghosh S. N., Sampat M. B., Jussawalla D. J. Further studies on the prognostic importance of Barr body frequency in human breast cancer: with discussion on its probable mechanism. J Surg Oncol. 1980;13(1):1–7. doi: 10.1002/jso.2930130102. [DOI] [PubMed] [Google Scholar]
  7. Coombes R. C., Dady P., Parsons C., McCready V. R., Ford H. T., Gazet J. C., Powles T. J. Assessment of response of bone metastases to systemic treatment in patients with breast cancer. Cancer. 1983 Aug 15;52(4):610–614. doi: 10.1002/1097-0142(19830815)52:4<610::aid-cncr2820520406>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  8. Coombes R. C., Neville A. M., Bondy P. K., Powles T. J. Failure of indomethacin to reduce hypercalcemia in patients with breast cancer. Prostaglandins. 1976 Dec;12(6):1027–1035. doi: 10.1016/0090-6980(76)90136-2. [DOI] [PubMed] [Google Scholar]
  9. Delides G. S., Garas G., Georgouli G., Jiortziotis D., Lecca J., Liva T., Elemenoglou J. Intralaboratory variations in the grading of breast carcinoma. Arch Pathol Lab Med. 1982 Mar;106(3):126–128. [PubMed] [Google Scholar]
  10. Ferreira S. H., Vane J. R. Prostaglandins: their disappearance from and release into the circulation. Nature. 1967 Dec 2;216(5118):868–873. doi: 10.1038/216868a0. [DOI] [PubMed] [Google Scholar]
  11. Fisher E. R., Gregorio R. M., Fisher B., Redmond C., Vellios F., Sommers S. C. The pathology of invasive breast cancer. A syllabus derived from findings of the National Surgical Adjuvant Breast Project (protocol no. 4). Cancer. 1975 Jul;36(1):1–85. doi: 10.1002/1097-0142(197507)36:1<1::aid-cncr2820360102>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  12. Higgs G. A., Eakins K. E., Mugridge K. G., Moncada S., Vane J. R. The effects of non-steroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur J Pharmacol. 1980 Aug 22;66(1):81–86. doi: 10.1016/0014-2999(80)90297-6. [DOI] [PubMed] [Google Scholar]
  13. Howat J. M., Harris M., Swindell R., Barnes D. M. The effect of oestrogen and progesterone receptors on recurrence and survival in patients with carcinoma of the breast. Br J Cancer. 1985 Feb;51(2):263–270. doi: 10.1038/bjc.1985.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Karmali R. A., Welt S., Thaler H. T., Lefevre F. Prostaglandins in breast cancer: relationship to disease stage and hormone status. Br J Cancer. 1983 Nov;48(5):689–696. doi: 10.1038/bjc.1983.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Kibbey W. E., Bronn D. G., Minton J. P. Prostaglandin synthetase and prostaglandin E2 levels in human breast carcinoma. Prostaglandins Med. 1979 Feb;2(2):133–139. doi: 10.1016/0161-4630(79)90048-x. [DOI] [PubMed] [Google Scholar]
  16. Lee E. T., Desu M. M. A computer program for comparing K samples with right-censored data. Comput Programs Biomed. 1972 Nov;2(4):315–321. doi: 10.1016/0010-468x(72)90019-0. [DOI] [PubMed] [Google Scholar]
  17. Meghji S., Sandy J. R., Scutt A. M., Harvey W., Harris M. Stimulation of bone resorption by lipoxygenase metabolites of arachidonic acid. Prostaglandins. 1988 Aug;36(2):139–149. doi: 10.1016/0090-6980(88)90301-2. [DOI] [PubMed] [Google Scholar]
  18. Powles T. J., Dady P. J., Williams J., Easty G. C., Coombes R. C. Use of inhibitors of prostaglandin synthesis in patients with breast cancer. Adv Prostaglandin Thromboxane Res. 1980;6:511–516. [PubMed] [Google Scholar]
  19. Rolland P. H., Martin P. M., Jacquemier J., Rolland A. M., Toga M. Prostaglandin in human breast cancer: Evidence suggesting that an elevated prostaglandin production is a marker of high metastatic potential for neoplastic cells. J Natl Cancer Inst. 1980 May;64(5):1061–1070. [PubMed] [Google Scholar]
  20. Seyberth H. W., Segre G. V., Morgan J. L., Sweetman B. J., Potts J. T., Jr, Oates J. A. Prostaglandins as mediators of hypercalcemia associated with certain types of cancer. N Engl J Med. 1975 Dec 18;293(25):1278–1283. doi: 10.1056/NEJM197512182932502. [DOI] [PubMed] [Google Scholar]
  21. Stamford I. F., Carroll M. A., Civier A., Hensby C. N., Bennett A. Identification of arachidonate metabolites in normal, benign and malignant human mammary tissues. J Pharm Pharmacol. 1983 Jan;35(1):48–49. doi: 10.1111/j.2042-7158.1983.tb04264.x. [DOI] [PubMed] [Google Scholar]
  22. Stamford I. F., MacIntyre J., Bennett A. Human breast carcinomas release prostaglandin-like material into the blood. Adv Prostaglandin Thromboxane Res. 1980;6:571–573. [PubMed] [Google Scholar]
  23. Unger W. G., Stamford I. F., Bennett A. Extraction of prostaglandins from human blood. Nature. 1971 Oct 1;233(5318):336–337. doi: 10.1038/233336b0. [DOI] [PubMed] [Google Scholar]
  24. Van Den Brenk H. A., Stone M., Kelly H., Orton C., Sharpington C. Promotion of growth of tumour cells in acutely inflamed tissues. Br J Cancer. 1974 Sep;30(3):246–260. doi: 10.1038/bjc.1974.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Vergote I. B., Laekeman G. M., Keersmaekers G. H., Uyttenbroeck F. L., Vanderheyden J. S., Albertyn G. P., Haensch C. F., De Roy G. J., Herman A. G. Prostaglandin F2 alpha in benign and malignant breast tumours. Br J Cancer. 1985 Jun;51(6):827–836. doi: 10.1038/bjc.1985.128. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Watson D. M., Kelly R. W., Hawkins R. A., Miller W. R. Prostaglandins in human mammary cancer. Br J Cancer. 1984 Apr;49(4):459–464. doi: 10.1038/bjc.1984.73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Watson D. M., Kelly R. W., Miller W. R. Prostaglandins and prognosis in human breast cancer. Br J Cancer. 1987 Sep;56(3):367–370. doi: 10.1038/bjc.1987.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Weigand R. A., Isenberg W. M., Russo J., Brennan M. J., Rich M. A. Blood vessel invasion and axillary lymph node involvement as prognostic indicators for human breast cancer. Cancer. 1982 Sep 1;50(5):962–969. doi: 10.1002/1097-0142(19820901)50:5<962::aid-cncr2820500526>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES